A Diaceutics quantitative physician survey reveals need for improved laboratory testing turnaround times for FLT3 in relapsed acute myeloid leukemia | Diaceutics

A Diaceutics quantitative physician survey reveals need for improved laboratory testing turnaround times for FLT3 in relapsed acute myeloid leukemia

June 13th, 2019



Researchers at Diaceutics uncovered the need for faster laboratory testing turnaround times (TAT) in an abstract accepted for publication by the European Hematology Association (EHA) for its annual meeting in June 2019. The abstract, entitled “FLT3 Testing in Relapsed Acute Myeloid Leukemia Setting Is Becoming Increasingly Common, But Laboratory Turnaround Times (TAT) May Be a Barrier to Treatment With Second Generation FLT3 Inhibitors,” analyzed the FLT3 testing behavior in relapsed acute myeloid leukemia (AML) over the course of a year. 

The researchers discovered an increase in awareness of the need for retesting in FLT3 and the need for faster TAT in the relapsed setting. However, the TAT results did not demonstrate an improvement in actual TAT, with the average TAT remaining suboptimal at 12.6 days., This may be due to the lack of an approved FLT3 inhibitor for secondline treatment in Europe. Lab TAT will be a key metric to monitor over the coming 12 to 18 months. 

For more information on these findings, contact services@diaceutics.com. 

Read Full Abstract here. 

Webinars & Podcasts

August 20th, 2019
Podcast: How Diaceutics is repairing the diagnostic testing ecoystem for patients worldwide
Diaceutics CEO, Peter Keeling joins Pat Kenny on Newstalk FM to discuss how analyzing Big Data to implement better diagnostic testing can help patients access better treatment options for cancer and other life-threatening diseases.
July 5th, 2019
Liquid Biopsy in NSCLC
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications